Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $631000.0.

  • Caribou Biosciences' Depreciation & Amortization (CF) fell 4638.91% to $631000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 1906.4%. This contributed to the annual value of $3.9 million for FY2024, which is 1140.43% up from last year.
  • As of Q3 2025, Caribou Biosciences' Depreciation & Amortization (CF) stood at $631000.0, which was down 4638.91% from $1.2 million recorded in Q2 2025.
  • Caribou Biosciences' Depreciation & Amortization (CF)'s 5-year high stood at $1.6 million during Q3 2023, with a 5-year trough of $221000.0 in Q1 2021.
  • In the last 5 years, Caribou Biosciences' Depreciation & Amortization (CF) had a median value of $617000.0 in 2023 and averaged $685315.8.
  • As far as peak fluctuations go, Caribou Biosciences' Depreciation & Amortization (CF) skyrocketed by 25088.89% in 2023, and later plummeted by 4638.91% in 2025.
  • Over the past 5 years, Caribou Biosciences' Depreciation & Amortization (CF) (Quarter) stood at $273000.0 in 2021, then soared by 85.35% to $506000.0 in 2022, then soared by 46.25% to $740000.0 in 2023, then skyrocketed by 60.0% to $1.2 million in 2024, then plummeted by 46.71% to $631000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $631000.0 in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.